Medroxyprogesterone interferes with ovarian steroid protection against coronary vasospasm

Cardiovascular disease, the major cause of death in post-menopausal women, can be reduced by re-placement of ovarian steroid hormones. To compare medroxyprogesterone with progesterone as the progestin in hormone replacement therapy from the standpoint of coronary artery vasospasm, we treated ovariectomized rhesus monkeys with physiological levels of estradiol-17 in combination with medroxyprogesterone or progesterone for four weeks. Coronary vasospasm in response to pathophysiological stimulation without injury showed that progesterone plus estradiol protected but medroxyprogesterone plus estradiol failed to protect, allowing vasospasm. We conclude that medroxyprogesterone in contrast to progesterone increases the risk of coronary vasospasm.

1. Gorodeski, G.I. & Utian, W.H. Epidemiology and risk factors of cardiovascular disease in postmenopausal women, in Treatment of the PostmenopausalWoman: Basic and Clinical Aspects (ed. Lobo, R.A.) 199−221 (Raven, New York, 1994).
2. Wenger, N.K., Speroff, L. & Packard, B. Cardiovascular health and disease in women. New Engl. J. Med. 329, 247−256 (1993). | Article | PubMed  | ISI | ChemPort |
3. The writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women, the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 273, 199−208 (1995). | ISI |
4. Lobo, R.A., Pickar, J.H., Wild, R.A., Walsh, B. & Hirvonen, E. Metabolic impact of adding medroxyprogesterone acetate to conjugated estrogen therapy in postmenopausal women. Obstet. Cynecol. 84, 987−995 (1994). | ChemPort |
5. Poulter, N.R. Venous thromboembolic disease and combined oral contraceptives: Results of international multicentre case-control study. Lancet 346, 1575−1582 (1995). | PubMed  | ISI |
6. Meirik, O. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet 346, 1582−1588 (1995). | PubMed  | ISI | ChemPort |
7. Jick, H., Jick, S.S., Gurewich, V., Myers, M.W. & Vasilakis, C. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 346, 1589−1593 (1995). | Article | PubMed  | ISI | ChemPort |
8. Bloemenkamp, W.M., Rosendaal, F.R., Helmerhorst, P.M., Buller, H.R. & Vandenbrouke, J.P. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet 346, 1593−1596 (1995). | Article | PubMed  | ISI |
9. Gilmore, J.P. Neural control of extraCellular volume in the human and nonhuman primate. in Handbook of Physiology. Section 2: The Cardiovascular System, Vol. Ill, Part 2 (eds. Shepherd, J.T. & Abboud, F.M.) 885−915 (American Physiological Society, Baltimore, Maryland, 1983).
10. Adams, M.R., Washburn, S.A., Wagner, J.D., Williams, J.K. & Clarkson, T.B. Arterial changes: Estrogen deficiency and effects of hormone replacement, in Treatment of the Postmenopausal Woman: Basic and Clinical Aspects (ed. Lobo, R. A.) 243−250 (Raven, New York, 1994).
11. Hermsmeyer, K. et al. Reactivity-based coronary vasospasm independent of atherosclerosis in rhesus monkeys. J. Am. Coll. Cardiol. (in the press).
12. Williams, C.L. & Stancel, G.M. Estrogens and Progestins. in Goodman and Gilman's The Pharmacological Basis of Therapeutics (eds. Hardman, J.G., Limbird, L.E., Molinoff, P.B., Ruddon, R.W., & Gilman, A.G.,) 1411−1440 (McGraw-Hill, New York, 1995).
13. Stanczyk, F.Z. Structure-function relationships, potency, and pharmacokinetics of progestogens. in Treatment of the Postmenopausal Woman: Basic and Clinical Aspects (ed. Lobo, R.A.) 69−89 (Raven, New York, 1994).
14. Resko, J.A., Ploem, J.G. & Stadelman, H.L. Estrogens in fetal and maternal plasma of the rhesus monkey. Endocrinology 98, 425−430 (1975).
15. Mishra, S.K. & Hermsmeyer, K. Inhibition of signal Ca²⁺ in dog coronary arterial vascular muscle Cells by Ro 40−5967. J. Cardiovasc. Pharmacol. 24, 1−7 (1994). | PubMed  | ISI | ChemPort |
16. Maseri, A., Davies, G., Hackett, D. & Kaski, J.C. Coronary artery spasm and vasoconstriction. Circulation 81, 1983−1990 (1990). | PubMed  | ISI | ChemPort |
17. Miller, V.M. & Vanhoutte, P.M. Progesterone and modulation of endothelium-dependent responses in canine coronaiy arteries. Am. J. Physiol. 261, R1022−R1027 (1991). | PubMed  | ISI | ChemPort |
18. Slayden, O.D., Hirst, J.J. & Brenner, R.M. Estrogen action in the reproductive tract of rhesus monkeys during antiprogestin treatment. Endocrinology 132, 1845−1856 (1993). | Article | PubMed  | ISI | ChemPort |
19. Hiroi, M. et al. Radioimmunoassay of serum medroxyprogesterone acetate (Provera) in women following oral and intravaginal administration. Steroids 26, 373−386 (1975.) | Article | PubMed  | ISI | ChemPort |
20. Resko, J.A., Norman, R.L., Niswender, G.D. & Spies, H.G. The relationship between progesterone and gonadotropins during the late luteal phase of the menstrual cycle in rhesus monkeys. Endocrinology 94, 128−135 (1974). | PubMed  | ISI | ChemPort |
21. Jiang, C.W., Sarrel, P.M., Lindsay, D.C., Poole-Wilson, P.A. & Collins, P. Progesterone induces endothelium-independent relaxation of rabbit coronary artery in vitro. Eur. J. Pharmacol. 211, 163−167 (1992). | Article | PubMed  | ISI | ChemPort |
22. Healy, B.PEPI in Perspective, good answers spawn pressing questions. JAMA 273, 240−241 (1995). | Article | PubMed  | ISI | ChemPort |
23. Belchetz, P.E. Hormonal treatment of postmenopausal women. New Engl. J. Med. 330, 1062−1071 (1994). | Article | PubMed  | ISI | ChemPort |

	Top

	Top